5.99
price down icon7.56%   -0.49
after-market 시간 외 거래: 6.00 0.010 +0.17%
loading
전일 마감가:
$6.48
열려 있는:
$6.24
하루 거래량:
2.18M
Relative Volume:
1.66
시가총액:
$752.55M
수익:
-
순이익/손실:
$-242.30M
주가수익비율:
-2.4153
EPS:
-2.48
순현금흐름:
$-192.10M
1주 성능:
-19.05%
1개월 성능:
-20.45%
6개월 성능:
-44.54%
1년 성능:
-10.86%
1일 변동 폭
Value
$5.89
$6.44
1주일 범위
Value
$5.89
$7.49
52주 변동 폭
Value
$5.88
$12.61

코젠트 바이오사이언시스 Stock (COGT) Company Profile

Name
명칭
Cogent Biosciences Inc
Name
전화
617-945-5576
Name
주소
275 WYMAN STREET, WALTHAM
Name
직원
0
Name
트위터
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
COGT's Discussions on Twitter

COGT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
COGT
Cogent Biosciences Inc
5.99 752.55M 0 -242.30M -192.10M -2.48
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

코젠트 바이오사이언시스 Stock (COGT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-07 개시 Scotiabank Sector Outperform
2024-12-11 다운그레이드 Needham Buy → Hold
2024-02-26 다운그레이드 Robert W. Baird Outperform → Neutral
2024-02-08 개시 Citigroup Buy
2023-12-11 다운그레이드 Wedbush Outperform → Neutral
2023-12-08 개시 JP Morgan Overweight
2023-04-28 개시 Robert W. Baird Outperform
2023-03-27 재개 H.C. Wainwright Buy
2022-12-14 개시 Needham Buy
2022-06-28 개시 Guggenheim Buy
2021-10-11 개시 H.C. Wainwright Buy
2021-06-09 재개 Jefferies Buy
2020-12-23 개시 Piper Sandler Overweight
2020-10-14 개시 Ladenburg Thalmann Buy
모두보기

코젠트 바이오사이언시스 주식(COGT)의 최신 뉴스

pulisher
08:35 AM

When Would Be The Best Time To Buy Cogent Biosciences Inc (NASDAQ: COGT) Stock? - stocksregister.com

08:35 AM
pulisher
03:53 AM

21,653 Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) Bought by Quantbot Technologies LP - Defense World

03:53 AM
pulisher
Mar 30, 2025

Swiss National Bank Sells 3,000 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

We're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn Rate - Yahoo Finance

Mar 29, 2025
pulisher
Mar 29, 2025

Proficio Capital Partners LLC Buys New Shares in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 29, 2025
pulisher
Mar 26, 2025

Cogent Biosciences Announces Multiple Poster Presentations - GlobeNewswire

Mar 26, 2025
pulisher
Mar 25, 2025

Cogent Biosciences Announces Multiple Poster Presentations At 2025 American Association For Cancer Research (AACR) Annual Meeting - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

Cogent's Cancer Breakthrough: 4 Precision Therapies Target KRAS, HER2, and Drug Resistance - StockTitan

Mar 25, 2025
pulisher
Mar 25, 2025

Charles Schwab Investment Management Inc. Boosts Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 25, 2025
pulisher
Mar 22, 2025

Bank of New York Mellon Corp Has $2.02 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Is Cogent Biosciences (COGT) Stock A Solid Choice Right Now? - Barchart

Mar 20, 2025
pulisher
Mar 20, 2025

Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? - Nasdaq

Mar 20, 2025
pulisher
Mar 18, 2025

Cogent Biosciences (COGT): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance

Mar 18, 2025
pulisher
Mar 17, 2025

Is Cogent Biosciences, Inc. (COGT) a Best Biotech Stock According to Billionaires? - Yahoo Finance UK

Mar 17, 2025
pulisher
Mar 14, 2025

Proficio Capital Partners LLC Invests $93,000 in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 14, 2025
pulisher
Mar 11, 2025

Gastrointestinal Stromal Tumor Treatment Market Size Report - openPR

Mar 11, 2025
pulisher
Mar 10, 2025

Cogent Biosciences (NASDAQ:COGT) Earns Sector Outperform Rating from Analysts at Scotiabank - Armenian Reporter

Mar 10, 2025
pulisher
Mar 09, 2025

Scotiabank Begins Coverage on Cogent Biosciences (NASDAQ:COGT) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Scotiabank Initiates Coverage of Cogent Biosciences (COGT) with Sector Outperform Recommendation - Nasdaq

Mar 08, 2025
pulisher
Mar 08, 2025

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.00 Average Target Price from Brokerages - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference - The Manila Times

Mar 07, 2025
pulisher
Mar 07, 2025

Cogent Biosciences initiated with an Outperform at Scotiabank - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

New York State Common Retirement Fund Has $180,000 Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Mar 06, 2025
pulisher
Mar 03, 2025

When the Price of (COGT) Talks, People Listen - Stock Traders Daily

Mar 03, 2025
pulisher
Feb 28, 2025

Buy Rating for Cogent Biosciences Backed by Promising Clinical Trial Results and Market Potential - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Q1 EPS Forecast for Cogent Biosciences Increased by Analyst - Defense World

Feb 28, 2025
pulisher
Feb 28, 2025

Needham & Company LLC Reiterates Hold Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World

Feb 28, 2025
pulisher
Feb 28, 2025

Cogent Biosciences Reports 2024 Financial Results and Clinical Progress - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Cogent Biosciences: Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Cogent Biosciences Announces SUMMIT Continues to Showcase - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Cogent Biosciences Reports 65% Improvement In Symptom Score From Bezuclastinib In NonAdvSM - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Cogent Biosciences announces expanded results from OLE portion of SUMMIT trial - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Yahoo Canada Finance

Feb 27, 2025
pulisher
Feb 27, 2025

Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Cogent Biosciences: Promising Pipeline and Market Opportunities Justify Buy Rating - TipRanks

Feb 26, 2025
pulisher
Feb 25, 2025

Cogent Biosciences (COGT) Surprises Wall Street with Narrower-Than-Expected Q4 Loss - HPBL

Feb 25, 2025
pulisher
Feb 25, 2025

Cogent Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 25, 2025
pulisher
Feb 25, 2025

Cogent Biosciences (COGT) Reports Q4 2024 Net Loss of $67.9 Mill - GuruFocus

Feb 25, 2025
pulisher
Feb 25, 2025

Cogent Biosciences, Inc. SEC 10-K Report - TradingView

Feb 25, 2025
pulisher
Feb 25, 2025

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

Can Cogent's Triple Catalyst Year Transform Rare Disease Treatment? 3 Key Trial Results Coming in 2025 - StockTitan

Feb 25, 2025
pulisher
Feb 22, 2025

Cogent Biosciences (COGT) Projected to Post Earnings on Monday - Defense World

Feb 22, 2025
pulisher
Feb 21, 2025

Long Term Trading Analysis for (COGT) - Stock Traders Daily

Feb 21, 2025
pulisher
Feb 14, 2025

Cogent Biosciences (NASDAQ:COGT) Trading Down 5.9%Time to Sell? - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

Leerink Partnrs Has Strong Forecast for COGT FY2025 Earnings - MarketBeat

Feb 14, 2025
pulisher
Feb 13, 2025

You might want to take a look at Cogent Biosciences Inc (COGT) now - SETE News

Feb 13, 2025
pulisher
Feb 11, 2025

Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) Target Price at $14.33 - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Cogent Biosciences (NASDAQ:COGT) Trading Down 5.9% – What’s Next? - Defense World

Feb 11, 2025
pulisher
Feb 11, 2025

Investing in Cogent Biosciences Inc (COGT) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News

Feb 11, 2025
pulisher
Feb 11, 2025

Is Cogent Biosciences (COGT) Outperforming Other Medical Stocks This Year? - Nasdaq

Feb 11, 2025
pulisher
Feb 11, 2025

Cogent Biosciences (NASDAQ:COGT) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Feb 11, 2025

코젠트 바이오사이언시스 (COGT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
자본화:     |  볼륨(24시간):